Julie Stancliff, DO
Psychiatry · Bel Air, MDNPI 1366656340
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,520 of the $57,338 with a category attached, or 93.3%. Alkermes, Inc. accounts for 97.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $18,623 and has fallen 98.8% since, to $226 in 2025. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $427.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$56K
- AbbVie$266
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$146
- Teva Pharmaceuticals USA, Inc.$138
- Otsuka America Pharmaceutical, Inc.$126
- Takeda Pharmaceuticals U.S.A., Inc.$111
- plus $419 from 8 others
What the payments were for
- Speaking & faculty fees$53,52093%
- Travel & lodging$1,8873%
- Food & beverage$1,8723%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 78 | $56,133 |
| AbbVie | 12 | $266 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $146 |
| Teva Pharmaceuticals USA, Inc. | 8 | $138 |
| Otsuka America Pharmaceutical, Inc. | 6 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $111 |
| USWM, LLC | 5 | $105 |
| Vanda Pharmaceuticals Inc. | 4 | $90 |
| E.r. Squibb & Sons, L.L.C. | 2 | $68 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Lundbeck LLC | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Corium, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$54,805
How this compares
$57,338 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $287,155 |
| VraylarCariprazine Hcl | 12 | $18,355 |
| Vilazodone Hcl | 22 | $2,824 |
| Clozapine | 41 | $2,708 |
| Aripiprazole | 27 | $2,318 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 34 | $2,090 |
| Bupropion XlBupropion Hcl | 65 | $1,722 |
| Hydroxyzine Hcl | 12 | $1,635 |
| Duloxetine Hcl | 65 | $1,596 |
| Buspirone Hcl | 59 | $1,440 |
| Doxepin Hcl | 38 | $1,206 |
| Quetiapine Fumarate | 35 | $1,072 |
| Fluoxetine Hcl | 39 | $1,039 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 57 | $945 |
| Escitalopram Oxalate | 49 | $909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $138 | $287,15518 claims |
| AbbVieVraylar | $266 | $18,35512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Bel Air
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Jamal FawazHagerstown$321K
- Thomas LaughrenRockville$283K
- Adam RothAnnapolis$210K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Paul LeberPotomac$85K
- Akira SawaBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.